Severe Psoriasis With Erythrodermic Rash Manifestation: A Case Report
DOI:
https://doi.org/10.52783/jns.v14.2711Keywords:
Factors, conditions, alternative health care, diabetesAbstract
Introduction: Severe psoriasis with generalized erythematous rash impacts on disability, disfiguration, mental health, and quality of life.
Case presentation: An Indonesian woman, 23 years old, complained of a chronic erythrodermic rash all over her body and scaly skin for two months. In addition, an unpleasant odor fluid oozes out from multiple erythematous rash lesions. The patient had a history of using herbal medicines and baths. The results of the supporting examinations showed increased leukocyte counts, anti-nuclear antibody (ANA) was detected, and a skin biopsy revealed psoriasis vulgaris. The patient received steroid therapy, and along the way, the patient experienced psychological problems while being treated in the hospital. The patient was an outpatient, was evaluated several times, and showed improvement.
Discussion: Psoriasis patients receive first-line treatment, and if it is not effective, biologic agent therapy can be considered. Psoriasis follow-up is important because, in its course, psoriasis is closely related to mental health and mortality, which is influenced by comorbidity and low socioeconomic status.
Conclusion: Mental health, psoriasis, skin biopsy, steroid.
Downloads
Metrics
References
Cita Rosita Sigit Prakoeswa, C., Afif Nurul Hidayati, A., Made Putri Hendaria, M., Listiawan, M. Y., Budi Utomo, B., Damayanti, D., Irmadita Citrashanty, I., Sylvia Anggraeni, S., Menul Ayu Umborowati, M., & Evy Ervianti, E. (2021). The profile of psoriasis vulgaris patients: A descriptive study. Berkala Ilmu Kesehatan Kulit Dan Kelamin, 33(3), 173–181.
Egeberg, A., Thyssen, J. P., Gislason, G. H., & Skov, L. (2016). Prognosis after hospitalization for erythroderma. Acta Dermato-Venereologica, 96(7), 959–962.
Global on report psoriasis. (2016).
Lo, Y., & Tsai, T.-F. (2021). Updates on the treatment of erythrodermic psoriasis. Psoriasis: Targets and Therapy, 59–73.
Michalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology, 31(2), 205–212.
Raharja, A., Mahil, S. K., & Barker, J. N. (2021). Psoriasis: a brief overview. Clinical Medicine, 21(3), 170–173.
Rahmayanti, N. D., Hidayati, A. N., Ervianti, E., & Muhdi, N. (2020). Association of psoriasis severity degree with self-esteem, depression and dermatology life quality index. Journal of Pakistan Association of Dermatologists, 30(1), 117–127.
Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 20(6), 1475.
Rofiq, K. S., Savitri, M., Rahmatika, A., Astari, L., Ashariati, A., & Bintoro, S. U. Y. (2024). A case report: A successfully treated erythrodermic mycosis fungoides with CHOP chemotherapy regiment and narrow band-UVB. Current Problems in Cancer: Case Reports, 15, 100300.
Sawitri, Listiawan MY, Fadila A, Wiratama PA, Murtiastutik D, & Ervianti E. (2022). Evaluation of Histopathology Findings of Clinically Confirmed Psoriasis Vulgaris. Berkala Ilmu Kesehatan Kulit Dan Kelamin (Periodical of Dermatology and Venereology), 35, 21–26.
Singh, R. K., Lee, K. M., Ucmak, D., Brodsky, M., Atanelov, Z., Farahnik, B., Abrouk, M., Nakamura, M., Zhu, T. H., & Liao, W. (2016). Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy, 93–104.
Sohrabi, C., Mathew, G., Maria, N., Kerwan, A., Franchi, T., & Agha, R. A. (2023). The SCARE 2023 guideline: updating consensus Surgical CAse REport (SCARE) guidelines. International Journal of Surgery, 109(5), 1136–1140.
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017). Psoriasis and comorbid diseases: epidemiology. Journal of the American Academy of Dermatology, 76(3), 377–390.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
